BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 11196156)

  • 1. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
    Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
    Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines.
    Seo T; Urasaki Y; Takemura H; Ueda T
    Anticancer Res; 2005; 25(2A):991-8. PubMed ID: 15868938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
    Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
    Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway.
    Yoshida A; Takemura H; Inoue H; Miyashita T; Ueda T
    Cancer Res; 2006 Jun; 66(11):5772-80. PubMed ID: 16740716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
    Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
    Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
    Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
    Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
    Grant S; Turner A; Nelms P; Yanovich S
    Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis.
    Ray S; Bullock G; Nuñez G; Tang C; Ibrado AM; Huang Y; Bhalla K
    Cell Growth Differ; 1996 Dec; 7(12):1617-23. PubMed ID: 8959329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells.
    Prenkert M; Uggla B; Tina E; Tidefelt U; Strid H
    Anticancer Res; 2009 Oct; 29(10):4071-6. PubMed ID: 19846953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
    Niitsu N; Ishii Y; Matsuda A; Honma Y
    Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
    Wang S; Vrana JA; Bartimole TM; Freemerman AJ; Jarvis WD; Kramer LB; Krystal G; Dent P; Grant S
    Mol Pharmacol; 1997 Dec; 52(6):1000-9. PubMed ID: 9396780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells.
    Paul S; Breuninger LM; Kruh GD
    Biochemistry; 1996 Nov; 35(44):14003-11. PubMed ID: 8909298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein.
    Benderra Z; Trussardi A; Morjani H; Villa AM; Doglia SM; Manfait M
    Eur J Cancer; 2000 Feb; 36(3):428-34. PubMed ID: 10708946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance.
    Gekeler V; Ise W; Sanders KH; Ulrich WR; Beck J
    Biochem Biophys Res Commun; 1995 Mar; 208(1):345-52. PubMed ID: 7887949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two distinct modes of oncoprotein expression during apoptosis resistance in vincristine and daunorubicin multidrug-resistant HL60 cells.
    Belhoussine R; Morjani H; Gillet R; Palissot V; Manfait M
    Adv Exp Med Biol; 1999; 457():365-81. PubMed ID: 10500812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
    Yang B; Keshelava N; Anderson CP; Reynolds CP
    Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of human leukemic cell lines to 1-beta-D-arabinofuranosylcytosine: characterization of an experimental model.
    Gariboldi MB; Ravizza R; Marras E; Perletti G; De Simone A; Piccinini F; Monti E
    Int J Oncol; 2001 Jun; 18(6):1245-9. PubMed ID: 11351258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells.
    Lutzky J; Astor MB; Taub RN; Baker MA; Bhalla K; Gervasoni JE; Rosado M; Stewart V; Krishna S; Hindenburg AA
    Cancer Res; 1989 Aug; 49(15):4120-5. PubMed ID: 2568167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A.
    Gollapudi S; Gupta S
    Anticancer Res; 1992; 12(6B):2127-32. PubMed ID: 1363515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.